Intelligence · Clinical Development
Pipeline search results
Programs matching “olaparib” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 11 pipeline programs matching "olaparib" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
OLAPARIB
AstraZeneca
Platinum Sensitive Relapsed Ovarian Cancer
1 trial -
Olaparib
AstraZeneca
Breast Cancer Metastatic
1 trial -
Olaparib 300mg tablets
AstraZeneca
Newly Diagnosed
1 trial -
Olaparib 300mg tablets
AstraZeneca
Relapsed Ovarian Cancer
1 trial -
OLAPARIB, BEVACIZUMAB
The George Institute
Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer
1 trial -
Olaparib
United Therapeutics Europe Ltd
Bile Duct Adenocarcinoma
1 trial -
Olaparib Continuous (28-Day cycle) 300 mg BD.
AstraZeneca
Metastatic Triple Negative Breast Cancer
1 trial -
AZD5363+Olaparib+Durvalumab
Hospital Authority, Hong Kong
Solid Tumor, Adult
1 trial -
Olaparib tablets, 150 mg
Sandoz Pty Ltd
Ovarian Cancer
1 trial -
olaparib
United Therapeutics Europe Ltd
Advanced Cancer
1 trial -
COBICISTAT , OLAPARIB
Disc Medicine
Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.